About AIV

Advanced In Vitro, LLC

Advanced In Vitro, LLC (AIV), founded in 2006, specializes in the development and application of physiologically relevant models for non-clinical research. With Innovation in mind, and working with vitro and ex vivo systems for over 25 years, a variety of invention disclosures have been publicized, including six directly associated with advancing organ slice technologies. Of these, the "game-changing" cryopreservation of 3-dimensional human lung slices has positioned this model as a readily accessible lung model for use "on-demand". Using AIV’s proprietary CryoViable™ freezing technology, human precision-cut lung slices (hPLuS) are created, banked and provided to researchers globally. Combined with Dr. Behrsing's Multi-CoS™ slicer modications, thousands of hPCLuS from each donor (ethically sourced and blinded of PII) can be created, allowing repeat donor interrogation, and multi-donor and disease state comparisons. The optimized protocols provided allow >4 weeks culture, allowing repeat exposure and chronic evaluation of tissues responses. With regulatory agencies such as the FDA and EPA increasingly embracing New Approach Methodologies, including the use of complex human-derived test systems to detect key events of adverse outcome pathways, talk to AIV about your NAMs needs!

AIV Provides

Opportunities to collaborate and purchase high quality, batch profiled, human CryoViable™ lung slices (other species upon request). Supplier of human precision-cut lung slices, which are available for sale.
The ability to custom generate, bank, and provide normal and disease slice models (liver and other organ slices to follow). We supply human emphysema, COPD, IPF, or fibrotic precision-cut slices when available.
Consulting for experimental design and study conduct using tissue slices in BSL2 compatible exposure and culture protocol. AIV provides precision-cut lung slices for such studies.
Extensive network of subcontractors for specialized evaluations/technologies, including airway and vessel contractility in precision-cut lung slices.

AIV is growing!

A large interest in the further development of 3D and other tissue slice technology has spurred the growth of AIV and recruitment of unmatched expertise! We now have contract staff highly skilled in quality operations and aseptic technique, as well as >20-year regulatory experience advising how best to further integrate NAMs into testing paradigms that can garner widespread acceptance. Additional expertise in immunology and laboratory management accelerates our development of the advanced tissue models…to the benefit of our collaborators and colleagues!

About the Founder

Advanced In Vitro, LLC was founded by Dr. Holger Behrsing to continue developing, and applying predictive in vitro models that are effective in reducing product development costs, eliminating animal research, and improving human health. He double majored in Biological Sciences and German (UC Santa Barbara), allowing him to study abroad in Germany and also conduct research at the Max-Planck Institute for Experimental Medicine before returning to the United States. While at the UC Davis he earned his Ph.D. in Pharmacology and Toxicology researching neuronal cellular signal transduction mechanisms. As a post-doctoral researcher at SRI International, he established 3-dimensional test systems modeling the liver and lung. Subsequently as PI, he continued to advance these models under two National Cancer Institute (NCI) R33 fast track funding awards, and relocated to Maryland to Head the Predictive Toxicology Lab Section (Leidos Biomedical Research, Inc.) closely supporting NCI efforts. Dr. Behrsing currently leads a Respiratory Toxicology Program where cutting edge models and assays are applied for product safety testing. He also serves the Environmental Protection Agency and Food and Drug Administration as a Special Government Employee advising on the use of New Approach Methodologies (NAMs) such as complex in vitro and ex vivo test systems that may be used in a regulatory setting. His breadth of experience is reflected by numerous peer reviewed publications.

"It is said the 21st century will see amazing advances in the field of biotechnology. I firmly believe the conception, development, and pragmatic application of innovative in vitro systems that accurately predict human response will redefine currently accepted product development practices." Dr. Holger P. Behrsing, Founder